Literature DB >> 26161442

LIF is a new p53 negative regulator.

Juan Liu1, Haiyang Yu1, Wenwei Hu1.   

Abstract

Leukemia inhibitory factor (LIF), a cytokine that belongs to the interleukin-6 family, regulates multiple important biological functions. Recently, we found that LIF is an important negative regulator of p53 in human colorectal cancer cells. LIF negatively regulates p53 protein levels and functions by activation of the Stat3 signaling pathway, which in turn induces the expression of ID1, the helix-loop-helix (HLH) protein inhibitor of differentiation and DNA binding. ID1 increases MDM2 expression at both mRNA and protein levels to accelerate p53 protein degradation. Overexpression of LIF increases chemoresistance of cultured colorectal cancer cells and colorectal xenograft tumors in a largely p53-dependent manner. Furthermore, LIF is overexpressed in a large percentage of human colorectal cancer specimens and LIF overexpression is associated with a poor prognosis in colorectal cancer patients. Our study revealed a new role of LIF in tumorigenesis through regulation of the p53 signaling pathway.

Entities:  

Keywords:  ID1; LIF; MDM2; Stat3; chemoresistance; p53

Year:  2015        PMID: 26161442      PMCID: PMC4493903     

Source DB:  PubMed          Journal:  J Nat Sci        ISSN: 2377-2700


  16 in total

1.  Leukemia inhibitory factor: a paracrine mediator of bone metabolism.

Authors:  Natalie A Sims; Rachelle W Johnson
Journal:  Growth Factors       Date:  2012-02-06       Impact factor: 2.511

2.  LIF mediates proinvasive activation of stromal fibroblasts in cancer.

Authors:  Jean Albrengues; Isabelle Bourget; Catherine Pons; Vincent Butet; Paul Hofman; Sophie Tartare-Deckert; Chloe C Feral; Guerrino Meneguzzi; Cedric Gaggioli
Journal:  Cell Rep       Date:  2014-05-22       Impact factor: 9.423

Review 3.  MDM2 is a central node in the p53 pathway: 12 years and counting.

Authors:  Gareth L Bond; Wenwei Hu; Arnold J Levine
Journal:  Curr Cancer Drug Targets       Date:  2005-02       Impact factor: 3.428

Review 4.  The leukemia inhibitory factor and its receptor.

Authors:  D P Gearing
Journal:  Adv Immunol       Date:  1993       Impact factor: 3.543

5.  Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas.

Authors:  Marcin Wysoczynski; Katarzyna Miekus; Kacper Jankowski; Jens Wanzeck; Salvatore Bertolone; Anna Janowska-Wieczorek; Janina Ratajczak; Mariusz Z Ratajczak
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

Review 6.  The effect of leukaemia inhibitory factor (LIF) on embryogenesis.

Authors:  R C Fry
Journal:  Reprod Fertil Dev       Date:  1992       Impact factor: 2.311

7.  Leukemia inhibitory factor is an anti-inflammatory and analgesic cytokine.

Authors:  L R Banner; P H Patterson; A Allchorne; S Poole; C J Woolf
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

8.  Leukemia inhibitory factor inhibits neuronal terminal differentiation through STAT3 activation.

Authors:  Cheil Moon; Joo-Yeon Yoo; Valéry Matarazzo; Young Kwan Sung; Esther J Kim; Gabriele V Ronnett
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

9.  p53 regulates maternal reproduction through LIF.

Authors:  Wenwei Hu; Zhaohui Feng; Angelika K Teresky; Arnold J Levine
Journal:  Nature       Date:  2007-11-29       Impact factor: 49.962

10.  Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.

Authors:  Shu-Chen Liu; Ngan-Ming Tsang; Wen-Che Chiang; Kai-Ping Chang; Chuen Hsueh; Ying Liang; Jyh-Lyh Juang; Kai-Ping N Chow; Yu-Sun Chang
Journal:  J Clin Invest       Date:  2013-11-25       Impact factor: 14.808

View more
  6 in total

1.  EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Authors:  Suryavathi Viswanadhapalli; Yiliao Luo; Gangadhara R Sareddy; Bindu Santhamma; Mei Zhou; Mengxing Li; Shihong Ma; Rajni Sonavane; Uday P Pratap; Kristin A Altwegg; Xiaonan Li; Annabel Chang; Alejandra Chávez-Riveros; Kalarickal V Dileep; Kam Y J Zhang; Xinlei Pan; Ramachandran Murali; Marek Bajda; Ganesh V Raj; Andrew J Brenner; Vijaya Manthati; Manjeet K Rao; Rajeshwar R Tekmal; Hareesh B Nair; Klaus J Nickisch; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2019-05-29       Impact factor: 6.261

Review 2.  Targeting LIF/LIFR signaling in cancer.

Authors:  Suryavathi Viswanadhapalli; Kalarickal V Dileep; Kam Y J Zhang; Hareesh B Nair; Ratna K Vadlamudi
Journal:  Genes Dis       Date:  2021-04-29

3.  Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction.

Authors:  Xuetian Yue; Yuhan Zhao; Cen Zhang; Jun Li; Zhen Liu; Juan Liu; Wenwei Hu
Journal:  Oncotarget       Date:  2016-01-26

4.  Influence of fine particulate matter and its pure particulate fractions on pulmonary immune cells and cytokines in mice.

Authors:  Zhouguang Jiao; Zhanbo Wen; Wenhui Yang; Lingfei Hu; Jinsong Li
Journal:  Exp Ther Med       Date:  2021-04-21       Impact factor: 2.447

5.  LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.

Authors:  Mengxing Li; Suryavathi Viswanadhapalli; Bindu Santhamma; Uday P Pratap; Yiliao Luo; Junhao Liu; Kristin A Altwegg; Weiwei Tang; Zexuan Liu; Xiaonan Li; Behnam Ebrahimi; Hui Yan; Yi Zou; Swapna Konda; Gangadhara R Sareddy; Zhenming Xu; Yidong Chen; Manjeet K Rao; Andrew J Brenner; Virginia G Kaklamani; Rajeshwar R Tekmal; Gulzar Ahmed; Ganesh V Raj; Klaus J Nickisch; Hareesh B Nair; Ratna K Vadlamudi
Journal:  Commun Biol       Date:  2021-10-29

6.  Functional Polymorphisms in the p53 Pathway Genes on the Genetic Susceptibility to Zika Virus Teratogenesis.

Authors:  Julia A Gomes; Eduarda Sgarioni; Igor A Vieira; Lucas R Fraga; Patrícia Ashton-Prolla; Ana Cláudia P Terças-Tretell; Juliana H da Silva; Bethânia F R Ribeiro; Marcial F Galera; Thalita M de Oliveira; Maria Denise F Carvalho de Andrade; Isabella F Carvalho; Lavínia Schuler-Faccini; Fernanda S L Vianna
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.